文献速递银屑病与炎症性皮肤病

苏金单抗治疗使银屑病患者生活质量与症状正常化:PROSE研究结果

Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-01

PROSE研究为前瞻性、非随机、多中心研究,按既往治疗史将中重度银屑病患者分为初治组(N=663)、传统系统治疗组(N=673)和生物制剂组(N=324),评估苏金单抗300 mg治疗52周的患者报告结局。第16周70.8%患者达到DLQI 0/1应答,各亚组间疗效与生活质量改善无显著差异,且持续至第52周,安全性良好。

要点

  • 第16周70.8%患者达到DLQI 0/1应答,初治组74.7%、传统系统组71.3%、生物制剂组61.7%。
  • FDLQI均值由基线11.5降至第16周2.5,各亚组均明显改善。
  • 无论既往治疗史如何,苏金单抗300 mg的疗效与生活质量改善均持续至第52周且耐受良好。

核心结论

  • 苏金单抗治疗使相当比例银屑病患者及其家庭的生活质量完全正常化,且不受既往治疗史影响。
  • 所有生活质量与疗效指标的改善持续至第52周,治疗耐受良好,未观察到新的安全性信号。

研究设计与样本

  • PROSE为前瞻性、非随机、多中心研究(NCT02752776)。
  • 按基线治疗史分为初治组(N=663)、传统系统治疗组(N=673)和生物制剂组(N=324)。
  • 评估苏金单抗300 mg治疗52周的患者报告结局、疗效与安全性。

主要发现

  • 第16周70.8%患者达到DLQI 0/1应答(初治74.7%、传统系统71.3%、生物制剂61.7%),效果持续至第52周。
  • FDLQI均值由基线11.5(初治11.3、传统系统11.4、生物制剂12.1)降至第16周2.5(初治2.5、传统系统2.3、生物制剂3.5)。
  • 第16周EQ-5D、疼痛/瘙痒/鳞屑NRS、HAQ-DI、TSQM及PBI均显著改善。
  • 生活质量改善与PASI及IGA mod 2011 0/1应答的大幅改善相关。
  • 各亚组间疗效或生活质量改善无有意义的差异。

关键数值与推荐

  • DLQI 0/1应答定义为第16周主要终点指标。
  • 苏金单抗剂量为300 mg,评估期52周。
  • IGA mod 2011 0/1应答用于评估疗效。

临床怎么用

  • 对中重度银屑病患者,无论既往是否使用过系统治疗或生物制剂,苏金单抗300 mg均可显著改善生活质量与疾病症状。
  • 治疗决策中可关注DLQI及FDLQI等患者报告结局,并将家庭影响纳入评估。

局限性

  • 研究为非随机设计。
  • 按治疗史分组,各组基线特征可能存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Psoriatic disease is associated with considerable impairment of quality of life (QoL). The PROSE study (NCT02752776) investigated the impact of secukinumab treatment on patient-reported outcomes (PRO) in patients with moderate to severe psoriasis stratified by their treatment history. METHODS: PROSE was a prospective, non-randomised, multicentre study. Patients were categorized at baseline according to treatment history as naïve [naïve to any systemic therapy (N = 663)], conventional systemic [previously exposed to ≥1 conventional systemic (CS) therapy (N = 673)] and biologics [previously exposed to ≥1 biologic therapy (N = 324)]. QoL PROs, efficacy and safety of secukinumab 300 mg were assessed for a period of 52 weeks. RESULTS: The primary objective was met with 70.8% patients achieving a Dermatology Life Quality Index (DLQI) 0/1 response at Week 16 (naϊve, 74.7%; CS, 71.3%; biologic, 61.7%), with effects sustained up to Week 52. Mean Family DLQI (FDLQI) score decreased from 11.5 at baseline (naϊve, 11.3; CS, 11.4; biologic, 12.1) to 2.5 at Week 16 (naϊve, 2.5; CS, 2.3; biologic: 3.5). Substantial improvements in EuroQoL 5-Dimension Health Questionnaire, Numeric Rating Scale for pain, itching and scaling, Health Assessment Questionnaire-Disability Index, Treatment Satisfaction Questionnaire for Medication, and Patient Benefit Index were also observed at Week 16. The QoL gains were associated with substantial improvements in Psoriasis Area and Severity Index and Investigator Global Assessment mod 2011 0/1 response. No meaningful difference was observed in the efficacy or QoL improvements across patient subpopulations. All QoL and efficacy parameter improvements were sustained up to Week 52. Secukinumab treatment was well-tolerated, and no new safety signals were observed. CONCLUSION: Secukinumab treatment resulted in complete normalization of QoL in a substantial proportion of psoriasis patients, and their families, regardless of their prior treatment history.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2020. PMID: 32426889. doi:10.1111/jdv.16632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。